Reading size

PACK IN HAND · ONE-PAGE CHECK

Medicine pack check sheet

Print this sheet or fill it in before speaking with a pharmacist or clinician. Copy only what is printed on the pack in hand. The published fields below are starting points from this record, not proof that your pack is the same product.

Published record starting point

Record display name
Avodart
Generic name / active ingredient
dutasteride
Dosage-form class
Dosage form and presentation as documented in the linked primary label
Route
Oral
Record reviewed
2026-08-23

Copy from the pack in hand

Source-linked reading points

  • Check AVODART, dutasteride, 0.5 mg per capsule, NDC 80725-712-04, oral soft gelatin capsule, actual pack and target market together. Although JALYN contains dutasteride, it is a combination product with tamsulosin; a shared ingredient, similar name or milligram number does not establish self-directed substitution, combination or proportional conversion.
  • The label identifies AVODART for symptomatic BPH in men with an enlarged prostate. Shared urinary or prostate wording does not establish that it can be self-combined, substituted or alternated with finasteride, tamsulosin, herbs or another urological product.
  • The U.S. label says the soft gelatin capsules should be swallowed whole and not chewed or opened. This is label information for this exact product; if swallowing difficulty, package damage, a similar appearance or someone else's experience raises a question about handling, have a pharmacist or clinician check the actual product first.
  • The U.S. label lists pregnancy as a contraindication and gives a specific warning about contact with leaking capsules by women who are or may be pregnant. It is safety information from this U.S. label, not a website handling plan for an actual contact, damaged pack or any individual situation; contact a local pharmacist, clinician or appropriate medical support promptly.

Reviewed presentation examples — compare every field

  • Dutasteride 0.5 mg per capsule; 90-capsule bottleNDC 80725-712-04

EDITORIAL RECORD

Who prepared and checked this page

Byline
OriginDrug Content Editorial
Review role
Public primary-source verification
Last reviewed
2026-08-23
Source record
2 clickable primary-source entry points are listed with this dossier.

The review role checks source traceability, stated market, document version and product-identity fields. It is not a claim of clinical licensure, prescribing authority or individual pharmacy service. Read the editorial policy.

Search records
Enlarged public-label image